S Goto1, M Sato, R Kaneko, M Itoh, S Sato, S Takeuchi. 1. The Institute of Bioregulation, Scarf-Kaikan 5F, 1-2, Sumiyoshicho, Naka-ku, Yokohama, Kanagawa, 2310013, Japan.
Abstract
PURPOSE: The presence of immunological dysfunction has not been well demonstrated in cancer patients. Recent studies have revealed that the immune response can be classified into types 1 and 2, and in the present work the immunological function of patients was studied from the perspective of these two types of response. METHODS: Types 1 and 2 immune response were evaluated by monitoring the production of various cytokines by peripheral blood mononuclear cells from 38 patients with advanced cancer of various organs and 20 healthy subjects. The usual immunological parameters, differential cell leukocyte counts, the level of T cell subsets (CD4 and CD8) and natural killer activity were also examined. RESULTS: The production of interleukin-2 (IL-2), interferon gamma, IL-10, IL-12 and tumor necrosis factor alpha was found to be significantly lower in the patients (75 +/- 57, 171 +/- 205, 40 +/- 34, 8 +/- 8, 1450 +/- 1010 pg/ml) than in healthy subjects (143 +/- 99, 422 +/- 296, 64 +/- 34, 16 +/- 10, 2550 +/- 950 pg/ml); however, the mean level of IL-4 in the patients seemed to be higher. The correlations between different cytokine levels suggested that they were produced differently. Lymphocyte counts were significantly lower in patients, but there was no difference in the other usual immunological parameters. CONCLUSIONS: Patients with advanced cancer are deficient in monocytes and the type 1 immune response. The measurement of various cytokines reported in this study provides a more sensitive and valuable tool for evaluating the function of cell-mediated immunity in cancer patients than do the usual tests.
PURPOSE: The presence of immunological dysfunction has not been well demonstrated in cancerpatients. Recent studies have revealed that the immune response can be classified into types 1 and 2, and in the present work the immunological function of patients was studied from the perspective of these two types of response. METHODS: Types 1 and 2 immune response were evaluated by monitoring the production of various cytokines by peripheral blood mononuclear cells from 38 patients with advanced cancer of various organs and 20 healthy subjects. The usual immunological parameters, differential cell leukocyte counts, the level of T cell subsets (CD4 and CD8) and natural killer activity were also examined. RESULTS: The production of interleukin-2 (IL-2), interferon gamma, IL-10, IL-12 and tumor necrosis factor alpha was found to be significantly lower in the patients (75 +/- 57, 171 +/- 205, 40 +/- 34, 8 +/- 8, 1450 +/- 1010 pg/ml) than in healthy subjects (143 +/- 99, 422 +/- 296, 64 +/- 34, 16 +/- 10, 2550 +/- 950 pg/ml); however, the mean level of IL-4 in the patients seemed to be higher. The correlations between different cytokine levels suggested that they were produced differently. Lymphocyte counts were significantly lower in patients, but there was no difference in the other usual immunological parameters. CONCLUSIONS:Patients with advanced cancer are deficient in monocytes and the type 1 immune response. The measurement of various cytokines reported in this study provides a more sensitive and valuable tool for evaluating the function of cell-mediated immunity in cancerpatients than do the usual tests.
Authors: Stefanie N Linch; Melissa J Kasiewicz; Michael J McNamara; Ian F Hilgart-Martiszus; Mohammad Farhad; William L Redmond Journal: Proc Natl Acad Sci U S A Date: 2016-01-04 Impact factor: 11.205
Authors: David D Walker; Travis D Reeves; Anna-Maria de Costa; Corinne Schuyler; M Rita I Young Journal: Cytokine Date: 2012-03-24 Impact factor: 3.861
Authors: Kotaro Sasaki; Xi Zhao; Angela D Pardee; Ryo Ueda; Mitsugu Fujita; Sarita Sehra; Mark H Kaplan; Lawrence P Kane; Hideho Okada; Walter J Storkus Journal: J Immunol Date: 2008-07-01 Impact factor: 5.422
Authors: Joyce Faber; Madeleen J Uitdehaag; Manon Spaander; Sabine van Steenbergen-Langeveld; Paul Vos; Marloes Berkhout; Cor Lamers; Hans Rümke; Hugo Tilanus; Peter Siersema; Ardy van Helvoort; Ate van der Gaast Journal: J Cachexia Sarcopenia Muscle Date: 2015-03-31 Impact factor: 12.910